Insulet Corporation (PODD) Q3 2023 Earnings Call Transcript
Insulet Corporation (NASDAQ:PODD ) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Deborah Gordon - Vice President, Investor Relations Jim Hollingshead - President...
Insulet (PODD) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Insulet (PODD) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics co...
Insulet Corporation: Still No Bargain
Today, we take a look at Insulet Corporation, a mid-cap medical device concern. The company is focused on developing and marketing insulin delivery systems for people with diabetes and has a 'best ...
Down -20.51% in 4 Weeks, Here's Why Insulet (PODD) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Insulet (PODD) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts...
Here's Why You Should Invest in Insulet (PODD) Stock for Now
Investors are optimistic about Insulet (PODD) on continued expansion in Omnipod's market access.
Down -21.98% in 4 Weeks, Here's Why Insulet (PODD) Looks Ripe for a Turnaround
Insulet (PODD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revisin...
Why Insulet (PODD) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Shares of Insulet Dropped This Week
Insulet makes a tubeless insulin pump. The company is coming off a strong second quarter.
Insulet (PODD) Loses -24.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Insulet (PODD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revisin...
Will Insulet (PODD) Beat Estimates Again in Its Next Earnings Report?
Insulet (PODD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Down -17.48% in 4 Weeks, Here's Why Insulet (PODD) Looks Ripe for a Turnaround
The heavy selling pressure might have exhausted for Insulet (PODD) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts...
Insulet (PODD) is an Incredible Growth Stock: 3 Reasons Why
Insulet (PODD) is well positioned to outperform the market, as it exhibits above-average growth in financials.
New weight loss drugs could mean a $25 billion drag on restaurants by 2025, says Mizuho's Dan Dolev
Matt Taylor, Jefferies analyst, and Dan Dolev, managing director at Mizuho Securities, join 'The Exchange' to discuss how new weight loss drugs could decline revenue for restaurant transaction plat...
Healthcare Equipment Stock Climbs on Upgrade
The shares of Insulet Corporation (NASDAQ:PODD) are higher before this morning's open, after Jefferies upgraded the medical equipment distributor to "buy" from "hold," with a price-target cut to $2...
Insulet shares rise as analysts say weight-loss drug fears may be overblown
Insulet Corp. shares PODD, -2.67% gained 4% premarket on Monday after Jefferies analysts upgraded the stock to buy from hold, saying its valuation looks attractive after the shares were dragged dow...
Related Companies